Skip to main content
. Author manuscript; available in PMC: 2013 Dec 12.
Published in final edited form as: Lab Invest. 2012 Oct 29;93(1):10.1038/labinvest.2012.144. doi: 10.1038/labinvest.2012.144

Figure 4.

Figure 4

Sorafenib induces cytochrome c release. (a) Huh7 cells treated with different concentrations of sorafenib or (b) with a various time periods were harvested and mitochondria were purified by subcellular fractionation. Cytochrome c in the supernatant was detected with anti-cytochrome c monoclonal antibody. Voltage-dependent anion-selective channel 1 (VDAC1) from total mitochondria was used as a control for equal protein loading. (c) Isolated mitochondria from hepatocellular carcinoma (HCC) cells were incubated with sorafenib. Cytochrome c release was assessed by western blotting with specific cytochrome c antibody. VDAC1 was set up for equal protein loading control. (d) Purified mouse liver mitochondria were incubated with different concentrations of sorafenib and cytochrome c release was measured by western blotting. VDAC1 was used as a control for equal protein loading. (e) Mitochondria were prepared from mouse liver tissue. The same amount of mitochondria was treated with sorafenib for time periods as indicated. Cytochrome c levels were detected by western blotting with cytochrome c antibody. VDAC1 was used as a control for equal protein loading.